Another study found that dihydromyricetin can induce the expression of miR-98–5p and reduce the level of IGF2, thereby reversing the resistance of HER2-positive breast cancer cells to trastuzumab (Zhang et al., 2022). This evidence concerns the gene ERBB2 and breast carcinoma.